

## Pan-Canadian Pharmaceutical Alliance: Negotiations being considered by each Province/Territory

**As of January 31, 2018**

The pCPA has recommended that negotiations for the following 13 brand name drug products be considered by each Province/Territory individually:

<b>Drug Product Brand Name (Generic Name)</b>	<b>Indication/Use</b>
<b>Actemra (tocilizumab)</b>	Used to treat polyarticular juvenile idiopathic arthritis (pJIA)
<b>Botox (onabotulinumtoxinA)</b>	Used to treat chronic migraine
<b>Botox (onabotulinumtoxinA)</b>	Used to treat overactive bladder
<b>Fycompa (perampanel)</b>	Used to treat seizures
<b>Genotropin (somatropin)</b>	Used to treat growth hormone deficiency and Turner's syndrome
<b>Humalog 200 units/ml (insulin lispro)</b>	Used to treat Type 1 and 2 diabetes
<b>Humira (adalimumab)</b>	Used to treat polyarticular juvenile idiopathic arthritis
<b>Jentadueto (linagliptin/metformin)</b>	Used to treat Type 2 diabetes
<b>Komboglyze (saxagliptin/metformin)</b>	Used to treat Type 2 diabetes
<b>Latuda (lurasidone)</b>	Used to treat schizophrenia
<b>Lodalis powder for oral solution (colesevelam)</b>	Used to treat hypercholesterolemia (line extension)
<b>Lucentis (ranibizumab)</b>	Used to treat choroidal neovascularization secondary to pathologic myopia
<b>Trisenox (arsenic trioxide)</b>	Used to treat acute promyelocytic leukemia

\*No new drug products since last update of December 31, 2017.

Factors considered by provinces and territories in pursuing individual drug negotiations include Canadian Drug Expert Committee (CDEC) or pan-Canadian Oncology Drug Review Expert Review Committee (pERC) recommendations, listing status of alternatives and the overall value of joint negotiations for the particular product.